| [1] |
Lopez-Kostner F,Lavery IC,Hool GR, et al.Total mesorectal excision is not necessary for cancers of the upper rectum[J]. Surgery, 1998, 124(4): 612-617.
|
| [2] |
Clinical Outcomes of Surgical Therapy Study Croup.A comparison of laparoscopically assisted and open colectomy forcolon cancer[J]. N Engl J Med, 2004, 350(20): 2050-2059.
|
| [3] |
Carden OJ,Rees M,Poston CJ, et al.Guidelines for resectionof colorectal cancer liver metastases[J]. Cut, 2006, 55 Suppl3: Sl-8.
|
| [4] |
Charnsangavej C,Clary B,Fong M, et al.Selection of patients for resection of hepatic colorectal metastases：expert consensus statement[J]. Ann Surg Oncol, 2006, 13(10): 1261-1268.
|
| [5] |
Roh MS,Colangelo LH,O'Connell MJ, et al.Preoperative multimodality therapy improves disease-free survival in patients wich carcinoma of the rectum：NSABP R-03[J]. J Clin Oncol, 2009, 27(31): 5124-5130.
|
| [6] |
Gunderson LL,Jessup JM,Sargent DJ, et al.Revised TN categorization for colon cancer based on national survival outcomes data[J]. J Clin Oncol, 2010, 28(2): 264-271.
|
| [7] |
Sargent DJ,Marsoni S,Thibodeau SN, et al.Defectivemismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer[J]. J Clin Oncol, 2010, 28(20): 3219-3226.
|
| [8] |
Nordlinger B,Sorbye H,Collette L, et al.Final results of the EORTC Intergroup randomized phaseⅢ study 40983[EPOC]evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases[J]. J Clin Oncol, 2007, 25(18)suppl: LBA5.
|
| [9] |
Ychou M,Hohenberger W,Thezenas S, et al.A randomizedphaseⅢ study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resectionof liver metastases from colorectal cancer[J]. Ann Oncol, 2009, 20(12): 1964-1970.
|
| [10] |
Chung KY,Shia J,Keme ny NE, et al.Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growch factor receptor byimmunohistochemistry[J]. J Clin Oncol, 2005, 23(9): 1803-1810.
|
| [11] |
Lièvre A,Bachet JB,Boige V, et al.KRAS mutations as an independent prognostic factor in patients with advanced colorectaI cancer treated with cetuximab[J]. J Clin Oncol, 2008, 26(3): 374-379.
|
| [12] |
Karapetis CS,Khambata-F ord S,Jonker DJ, et al.K-rasmutations and benefit from cetuximab in advanced colorectal cancer[J]. N Engl J Med, 2008, 359(17): 1757-1765.
|
| [13] |
Di Nicolantonio F,Martini M,Molinari F, et al.Wild-type BRAF is required for response to panituniumab or cetuximab in metastatic colorectal cancer[J]. J Clin Oncol, 2008, 26(35): 5705-5712.
|
| [14] |
Maughan TS,Adams R,Smith CG, et al.Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy(CT)in first-lineadvanced colorectal cancer(aCRC)：Mature results of theMRC COIN trial[J]. J Clin Oncol, 2010, 28(15): 3502.
|